Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - human papillomavirus (hpv) 11 l1 protein 40ug;  ; human papillomavirus (hpv) 16 l1 protein 60ug;  ; human papillomavirus (hpv) 18 l1 protein 40ug;  ; human papillomavirus (hpv) 31 l1 protein 20ug;  ; human papillomavirus (hpv) 33 l1 protein 20ug;  ; human papillomavirus (hpv) 45 l1 protein 20ug;  ; human papillomavirus (hpv) 52 l1 protein 20ug;  ; human papillomavirus (hpv) 58 l1 protein 20ug;  ; human papillomavirus (hpv) 6 l1 protein 30ug;   - suspension for injection - 0.5 ml - active: human papillomavirus (hpv) 11 l1 protein 40ug   human papillomavirus (hpv) 16 l1 protein 60ug   human papillomavirus (hpv) 18 l1 protein 40ug   human papillomavirus (hpv) 31 l1 protein 20ug   human papillomavirus (hpv) 33 l1 protein 20ug   human papillomavirus (hpv) 45 l1 protein 20ug   human papillomavirus (hpv) 52 l1 protein 20ug   human papillomavirus (hpv) 58 l1 protein 20ug   human papillomavirus (hpv) 6 l1 protein 30ug   excipient: aluminium as amorphous aluminium hydroxyphosphate sulfate adjuvant histidine polysorbate 80 sodium borate sodium chloride water for injection - gardasil 9 is indicated in females aged 9 through 45 years for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine). gardasil 9 is indicated in males 9 through 45 years of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by hpv types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).

Izrael - angličtina - Ministry of Health

merck sharp & dohme israel ltd - protein l1 (type 11); protein l1 (type 16); protein l1 (type 18); protein l1 (type 6) - suspension for injection - protein l1 (type 18) 20 mcg / 0.5 ml; protein l1 (type 6) 20 mcg / 0.5 ml; protein l1 (type 11) 40 mcg / 0.5 ml; protein l1 (type 16) 40 mcg / 0.5 ml - combinations - combinations - gardasil is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, and 18 (which are included in the vaccine). gardasil is indicated in males 9 through 26 years* of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by hpv types 6, 11, 16, and 18 (which are included in the vaccine). *immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations..

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - human papillomavirus (hpv) 11 l1 protein 80 µg/ml;  ; human papillomavirus (hpv) 16 l1 protein 80 µg/ml;  ; human papillomavirus (hpv) 18 l1 protein 40 µg/ml;  ; human papillomavirus (hpv) 6 l1 protein 40 µg/ml;   - solution for injection - active: human papillomavirus (hpv) 11 l1 protein 80 µg/ml   human papillomavirus (hpv) 16 l1 protein 80 µg/ml   human papillomavirus (hpv) 18 l1 protein 40 µg/ml   human papillomavirus (hpv) 6 l1 protein 40 µg/ml   excipient: aluminium as amorphous aluminum hydroxyphosphate sulphate borax histidine polysorbate 80 sodium chloride water for injection - gardasil is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16 and 18 (which are included in the vaccine). gardasil is indicated in males 9 through 26 years of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infections caused by hpv types 6, 11, 16 and 18 (which are included in the vaccine). *immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hpv type 6 l1 protein, quantity: 20 microgram; hpv type 11 l1 protein, quantity: 40 microgram; hpv type 16 l1 protein, quantity: 40 microgram; hpv type 18 l1 protein, quantity: 20 microgram - injection, suspension - excipient ingredients: aluminium; histidine; polysorbate 80; borax; water for injections; sodium chloride - gardasil is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by human papillomavirus (hpv) types 6, 11, 16, and 18 (which are included in the vaccine). gardasil is indicated in males 9 through 26 years of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by hpv types 6, 11, 16, and 18 (which are included in the vaccine). *immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations.

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - human papillomavirus type 18 l1 protein; human papillomavirus type 16 l1 protein - suspension for injection

Spojené státy - angličtina - NLM (National Library of Medicine)

teva women's health, inc. - human adenovirus e serotype 4 strain cl-68578 (unii: fkd3duk39i) (human adenovirus e serotype 4 strain cl-68578 - unii:fkd3duk39i) - human adenovirus e serotype 4 strain cl-68578 32000 [tcid_50] - adenovirus type 4 and type 7 vaccine, live, oral is a vaccine indicated for active immunization for the prevention of febrile acute respiratory disease caused by adenovirus type 4 and type 7. adenovirus type 4 and type 7 vaccine, live, oral is approved for use in military populations 17 through 50 years of age. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to pregnant females [see pregnancy (8.1)] . it is not known whether adenovirus type 4 and type 7 vaccine, live, oral can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. naturally occurring infection with adenoviruses has been associated with fetal harm. pregnancy should be avoided for 6 weeks following receipt of vaccine. severe allergic reaction (e.g., anaphylaxis) to any component of adenovirus type 4 and type 7 vaccine, live, oral is a contraindication [see description (11)]. adenovirus type 4 and type 7 vaccine, live, oral should not be administered to individuals incapable of swa

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. waarderweg 39 - human papillomavirus type 6 l1 protein, human papillomavirus type 11 l1 protein, human papillomavirus type 16 l1 protein, human papillomavirus type 18 l1 protein - suspension for i/m injection - 20mcg/dose+ 40mcg/dose+ 40mcg/dose+ 20mcg/dose

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. waarderweg 39 - human papillomavirus type 6 l1 protein, human papillomavirus type 11 l1 protein, human papillomavirus type 16 l1 protein, human papillomavirus type 18 l1 protein - suspension for i/m injection - 20mcg/dose+ 40mcg/dose+ 40mcg/dose+ 20mcg/dose

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. waarderweg 39 - human papillomavirus type 6 l1 protein, human papillomavirus type 11 l1 protein, human papillomavirus type 16 l1 protein, human papillomavirus type 18 l1 protein - suspension for i/m injection - 20mcg/dose+ 40mcg/dose+ 40mcg/dose+ 20mcg/dose

Arménie - angličtina - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

merck sharp & dohme b.v. waarderweg 39 - human papillomavirus type 6 l1 protein, human papillomavirus type 11 l1 protein, human papillomavirus type 16 l1 protein, human papillomavirus type 18 l1 protein - suspension for i/m injection - 20mcg/dose+ 40mcg/dose+ 40mcg/dose+ 20mcg/dose